Breaking News Headlines Today | Ground News

New Year’s Sale — Build a balanced news diet with 40% off Vantage

Taiwan News image

News from Taiwan News

Ground News rates Taiwan News’s media bias as Lean Left. This rating is based on a combination of the media bias ratings of a Center rating from Ad Fontes Media, a leanLeft rating from Media Bias/Fact Check .

Taiwan News’s aggregated factuality score is Very High. Factuality is assigned by combining fact check, credibility, and reliability ratings from Ad Fontes Media and Media Bias/Fact Check.

Information about Taiwan News

Where is Taiwan News located?TaiwanTaiwan News's Website Taiwan News's Twitter Taiwan News's Wikipedia

Media Bias Ratings

Average Bias Rating:

Lean Left

Center

byAd Fontes Media

Lean Left

byMedia Bias/Fact Check

Do you disagree?

Edit bias

Learn more about Media Bias Ratings.

Factuality

Learn more about Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top Taiwan News News

ABL Bio Receives Upfront Payment for License, Research and Collaboration Agreement for Grabody Platform and Equity Investment from Lilly

United States · United States

ABL Bio Receives Upfront Payment for License, Research and Collaboration Agreement for Grabody Platform and Equity Investment from Lilly

56% Center coverage: 39 sources

Secured a total of 55 million in R&D funding, including 40 million in upfront payment and 15 million in equity investment See the Story

Caliway Submits CBL-514 for FDA Phase 2 Weight Management Trial

United States · United States

Caliway Submits CBL-514 for FDA Phase 2 Weight Management Trial

59% Center coverage: 36 sources

NEW TAIPEI CITY, Dec. 25, 2025 /PRNewswire/ -- Caliway Biopharmaceuticals (TWSE: 6919) today announced that it has completed the submission of an Investigational New Drug (IND) application to the U.S. FDA for a Phase 2 clinical study of its world's first large-area localized fat reduction drug candidate, CBL-514, for the weight management indication. This submission accelerates the clinical development of CBL-514 in combination with GLP-1R agoni…See the Story

YY Group Reports Unaudited First Half 2025 Earnings Results Highlighting Strong Revenue and Gross Profit Growth

Singapore · Singapore

YY Group Reports Unaudited First Half 2025 Earnings Results Highlighting Strong Revenue and Gross Profit Growth

46% Center coverage: 13 sources

/PRNewswire/ -- YY Group Holding Limited (NASDAQ: YYGH) ("YY Group" or the "Company"), a global leader in on-demand workforce solutions and integrated...See the Story

Breaking News Topics Related to Taiwan News